Atossa Genetics Inc
$ 2.58
-41.25%
11 Jun - close price
- Market Cap 22,174,400 USD
- Current Price $ 2.58
- High / Low $ 2.81 / 2.52
- Stock P/E N/A
- Book Value 3.54
- EPS -4.37
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.46 %
- ROE -0.79 %
- 52 Week High 19.35
- 52 Week Low 2.52
About
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
Analyst Target Price
$22.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-03-25 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-25 | 2024-11-12 | 2024-08-12 | 2024-04-01 | 2024-03-28 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -1.11 | -1.34 | -0.07 | -0.07 | -0.05 | -0.05 | -0.0575 | -0.05 | -0.05 | -0.09 | -0.05 | -0.08 |
| Estimated EPS | -0.0667 | -1.1433 | -0.06 | -0.06 | -0.07 | -0.0633 | -0.06 | -0.06 | -0.07 | -0.06 | -0.07 | -0.06 |
| Surprise | -1.0433 | -0.1967 | -0.01 | -0.01 | 0.02 | 0.0133 | 0.0025 | 0.01 | 0.02 | -0.03 | 0.02 | -0.02 |
| Surprise Percentage | -1564.1679% | -17.2046% | -16.6667% | -16.6667% | 28.5714% | 21.0111% | 4.1667% | 16.6667% | 28.5714% | -50% | 28.5714% | -33.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATOS
2026-06-11 15:40:21
U.S. stocks saw gains midway through trading, with the Nasdaq Composite, Dow, and S&P 500 all rising. Driven Brands Holdings Inc (NASDAQ: DRVN) reported strong first-quarter earnings, while several other companies experienced significant stock movements based on corporate news and financial results. Oil prices rose, gold and silver fell, and producer prices increased, while initial jobless claims reached a three-month high.
2026-06-11 13:09:31
Atossa Therapeutics Inc. (NASDAQ: ATOS) shares fell 30% in premarket trading after announcing a registered direct offering expected to raise $4.5 million. The company entered into an agreement with institutional investors to sell 1,363,638 shares of common stock at $0.18 par value, along with warrants for an additional 2,727,276 shares. The proceeds will be used for clinical development, working capital, and general corporate purposes.
2026-06-11 12:40:21
Atossa Therapeutics, Inc. announced a registered direct offering raising approximately $4.5 million in gross proceeds. The clinical-stage biopharmaceutical company is selling over 1.3 million shares and accompanying warrants, with potential for an additional $12 million if warrants are fully exercised. The proceeds will fund clinical development and general corporate purposes, while InvestingPro analysis highlights the company's significant cash burn.
2026-06-11 12:11:33
Atossa Therapeutics Inc. has raised $4.5 million in gross proceeds through a registered direct offering to institutional investors, selling 1,363,638 shares and an equal number of Series A and B warrants. The biopharmaceutical company plans to use the funds for clinical development, working capital, and general corporate purposes. This capital raise, despite a 50% year-to-date stock decline, comes as the company continues to advance its lead product candidate, (Z)-endoxifen, and has recently achieved significant regulatory and clinical milestones.
2026-06-11 12:05:33
This article lists 12 healthcare stocks experiencing significant movement in Thursday's pre-market session, categorized into gainers and losers. It highlights specific companies like Propanc Biopharma, 60 Degrees, Quantum Cyber, Silexion Therapeutics, Genenta Science, and CEL-SCI as gainers, and Atossa Therapeutics, Purple Biotech, Humacyte, GlucoTrack, Aditxt, and Basel Medical Group as losers, providing their stock performance and market capitalization.
2026-06-11 12:03:33
Atossa Therapeutics has entered into an agreement with institutional investors for a registered direct offering of common stock and warrants, priced at $3.30 per share. This offering is expected to net approximately $4.1 million, with potential additional gross proceeds of about $12 million from the full exercise of warrants. The company plans to utilize these funds for clinical development, working capital, and general corporate purposes.
